Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress

Dateline City:

KENILWORTH, N.J.

In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from three studies investigating the use of
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,
in combination with three other immunotherapies – epacadostat, IMLYGICTM
(talimogene laherparepvec), and ipilimumab – in patients with advanced
melanoma.
Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]orAn Phan, [phone]orInvestors:Teri Loxam, (908) 740-1986orJustin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Product News - November 21, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news